2008). Consistent with the dysphoric effects of k-agonist drugs and natural k-opioids isolated from the plant Salvia divinorum, endogenous dynorphins encode a component of the anxiogenic and dysphoric responses to stressful experience.
Thus, k-opioid antagonists show promise as therapeutic tools to promote stress resilience that may be effective in treating certain forms of anxiety, depression, and addiction disorders, as stress-hypersensitivity exacerbates each of these syndromes. However, selective k-opioid antagonists have been known since their initial development by Portoghese and Takemori more than 20 years ago to have remarkably long durations of action. Although this property might be considered a therapeutic advantage (as infrequent dosing may be sufficient and missed doses would be less concerning), the lack of understanding of its basis has slowed drug development. We recently reported (Bruchas et al, 2007; Melief et al, 2010) that the long action was not a result of k-receptor downregulation or drug persistence, but rather that these ligands were not truly competitive antagonists; instead their effects were caused by the activation of c-Jun N-terminal kinase (JNK) following k-receptor binding (Figure 1 ). We think that JNK activation phosphorylates a component of the k-receptor signaling complex, thus preventing Gprotein activation and causing longlasting receptor inactivation. This mechanism predicts that low-efficacy ligands that bind to k-receptors without activating JNK may be shortacting antagonists. Conventional, competitive k-antagonists may more easily gain approval.
The therapeutic promise of k-agonists has also been recently revived by studies showing that their dysphoric effects require activation of G-protein receptor kinase, arrestin recruitment and subsequent p38 MAPK activation, whereas their analgesic effects do not (Bruchas and Chavkin, 2010) . As evident from ligands initiating m-opioid signaling, some analgesic opioids including fentanyl effectively recruit arrestin, whereas morphine is an excellent analgesic, but does not recruit arrestin. The realization that different agonists binding to the same receptor can produce different actions has been variously called 'biased agonism', 'functional selectivity', and 'ligand directed signaling' (see Melief et al, 2010) . On the basis of this concept, an analgesic k-opioid that did not recruit arrestin might not produce dysphoria (Figure 1) . A formulation of such a ligand, combined with a peripherally restricted k-antagonist to block the constipating and diuretic effects, might result in the long-sought nonaddictive opioid analgesic. These are exciting times in the k-world. (Lin et al, 1998) , appears to be an important ALS initiator. Importantly for the investigation of motor neuron disease, animal models using TDP-43 mutations have been developed, which afford a new model for the study of potential ALS-related drug therapies (Wegorzewska et al, 2009 ).
Biomarkers
ALS largely remains a clinical diagnosis based on the presence of upper and lower motor neuron signs that can be observed on physical examination and supported by electrophysiological studies and exclusion of other etiologies using serological and imaging studies. Current efforts are underway with both large consortia and individual groups to identify biomarkers from tissue or fluids that can establish the diagnosis early in the course of disease as well as an assessment of disease progression, identification of ALS subtypes, prediction of disease prognosis, and assessment of the therapeutic efficacy of drug candidates.
ALS Therapeutics: Small Molecules and Antisense Technologies
Recent advances in the identification of specific genes, which can cause ALS, have fueled the speculation that ALS may be a disease amenable to gene silencing technologies. For the most common ALS disease related gene (SOD1), both RNAi and antisense technologies have been used in transgenic mutant SOD1 animal models of ALS to show effective reduction of the SOD1 protein (Miller et al, 2005) . A phase 1 safety trial using the CSF delivery of antisense oligonucleotides targeting SOD1 is now underway in patients with SOD1-mediated ALS (www.clinicaltrials.gov).
Cellular Therapy/IPS Cells
Perhaps the most important breakthrough in stem cell biology and its applicability to human diseases has been the ability to reprogram somatic cells into induced pluripotent stem cells (iPSC) using forced expression of the transcription factors Klf-4, Sox-2, Oct-4, and c-Myc, first in rodent, and then from human skin fibroblasts (Yu et al, 2007) . Current efforts are underway from different investigators to create iPSC-derived neural stem cells from ALS patients. These iPSCs can subsequently be differentiated into multiple nervous system subtypes to aid in the understanding of cellspecific contributions to the development of ALS, screening for potential neuroprotective and neuroregenerating compounds, and potentially for their therapeutic potential in cell transplantation. The ability of specific CNS cells, such as astroglia, to alter ALS outcomes has been recently shown preclinically (Lepore, 2008) . In parallel, the first commercial attempt to develop cellular-based therapies for ALS has entered into clinical trial. The proper cell for therapy is controversial and efforts, to date, appear to lack rigorous preclinical/ drug discovery science. However, the first challenge in this invasive-type therapy is the development of appropriate surgical methods to deliver cells intraspinally to patientsFand excellent efforts toward that goal appear underway in a recent phase 1 trial (www.clincialtrials.gov).
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Yu J, Vodyanik MA, Smuga-Otto K, AntosiewiczBourget J, Frane JL, Tian S et al (2007) . Induced pluripotent stem cell lines derived from human somatic cells. (eg, Gotlib et al, 2010) exhibit low striatal response to rewarding stimuli, such as money or happy facial expressions. This altered brain function has been observed during the anticipation of reward and the receipt of reward, suggesting that adolescent depression involves changes in both the motivation to obtain reward and the enjoyment of rewards once obtained.
In addition, there is also some evidence that adolescents with depression exhibit more reactivity in prefrontal regions thought to have a role in regulating response to reward stimuli. Consistent with the findings of increased anterior cingulate response to reward in adults with depression, adolescents with depression exhibit less response in the medial prefrontal cortex (PFC) (Forbes et al, 2009) , an area that is a key target, along with the striatum, of midbrain dopamine neurons. The medial PFC is a critical region in reward circuits, and its efferent connections include the ventral striatum (Haber and Knutson, 2010) .
The study of reward function has potential to elucidate many processes in the development and course of adolescent depression. Developmental findings that reward function changes with puberty and is associated with depressive symptoms in healthy adolescents (Forbes et al, 2010b) can inform the etiology of adolescent depression. Although the treatment implications of reward function research remain to be explored, initial findings suggest that adolescents' neural response to reward predicts symptom level and severity at outcome, as well as rate of symptom decrease during treatment for depression (Forbes et al, 2010a; Figure 1 In adolescents with major depressive disorder, (a) response to reward anticipation in the striatum (left) and medial prefrontal cortex (right) at treatment entry was related to (b) rate of reduction in anxiety symptoms during an 8-week treatment with either cognitive-behavioral therapy or cognitive-behavioral therapy plus pharmacotherapy using selective serotonin reuptake inhibitors. Faster rate of decline in anxiety symptoms was predicted by greater striatal reactivity and lower medial prefrontal reactivity before treatment. Error bars represent 1SE of the mean at each time point. SCARED, Screen for Childhood Anxiety and Related Disorders (anxiety symptom measure); T1, pre-treatment; T2, treatment session 2; T3, treatment session 4; T4, treatment session 6; T5, treatment session 8 (post-treatment). The figure is based on the data published in Forbes et al (2010a).
